Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transition Therapeutics and Ellipsis Neurotherapeutics have initiated clinical development for their lead product AZD-103, a promising disease-modifying therapeutic candidate for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
AZD-103 is part of a new class of therapeutics that provides significant advantages over the current products on the market which only treat disease symptoms.
Strong preclinical data have confirmed AZD-103’s safety profile and potential as a disease-modifying therapeutic for the treatment of the disease. AZD-103 can disaggregate amyloid-beta fibrils and reduce amyloid-beta load, improve cognitive function and extend overall survival.
“We plan to submit an IND for approval of a phase I clinical trial by the end of the year and in parallel commence the additional preclinical studies required for the phase II clinical trial expected to begin in late Q3 of 2006” said Dr Tony Cruz, chairman and CEO of Transition.